Mounjaro 12.5 mg is prescribed for the following medical indications: 🔹 Type 2 Diabetes Mellitus: Long-term blood sugar control in adult patients when previous doses (5 mg, 7.5 mg, 10 mg) did not provide sufficient glycemic control. 🔹 Weight Management: Treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of cardiovascular complications, hypertension, or dyslipidemia.

Dosage and administration

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 12.5 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The drug is administered once a week. Transition to the 12.5 mg dose is only possible after successful completion of at least a 4-week course at the 10 mg dosage. Injection Technique: Subcutaneous injection into the abdomen, front of the thigh, or upper arm. Rotate the injection site weekly. Timing: Independent of meals. It is recommended to choose the same day of the week for ease of tracking. Storage: Store in the refrigerator at 2°C–8°C. Do not freeze! After starting use, the pen can be stored at temperatures up to 30°C for 21 days.

⛔ Oncological Risks: Personal or family history of medullary thyroid carcinoma. ⛔ Endocrine Diseases: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). ⛔ Pregnancy and Lactation: Use is contraindicated. When planning a pregnancy, use should be discontinued 2 months in advance. ⛔ Type 1 Diabetes Mellitus: Not intended for the treatment of this type of disease. ⛔ Severe GI Disorders: Severe gastroparesis or history of pancreatitis. ⛔ Allergy: Hypersensitivity to tirzepatide.

When using the 12.5 mg dosage, side effects related to the body's adaptation to a high concentration of the drug are possible: 🤢 Gastroenterological: Nausea, diarrhea, vomiting, dyspepsia, abdominal pain. Usually pronounced in the first weeks after a dose increase. 🍽️ Reduced Appetite: Rapid satiety and changes in taste preferences are frequently observed. 🏃♂️ General: Fatigue, feeling of weakness, sometimes dizziness (especially with low calorie intake). ⚠️ Serious Warnings: Monitoring of renal function is necessary in cases of severe vomiting (dehydration risk). Rarely — acute pancreatitis or gallbladder disease. 💉 Skin Reactions: Mild redness or itching at the injection site.

Mounjaro KwikPen 12.5 — Tirzepatide 12.5 mg, 1 pcs, Eli Lilly India

100% original product

Active ingredient

Tirzepatide

Manufacturer

Eli Lilly India

Dosage 12.5 mg

Dosage form Prefilled pen

Pens per pack 1

Mounjaro KwikPen 12.5 — Tirzepatide 12.5 mg (1 Pen / 4 Doses)

Name: Mounjaro KwikPen 12.5
Brand: Eli Lilly India
SKU: PROD-271
Price: 26124 UAH
Availability: InStock

26124₴ ~~27359₴~~ -5%

Mounjaro KwikPen 12.5 mg (Tirzepatide) is a high-dose form of one of the most advanced medications for the treatment of type 2 diabetes and chronic weight management. Tirzepatide is unique as a dual receptor agonist: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The 12.5 mg dosage is intended for patients requiring intensive therapy to achieve target metabolic goals.

Manufacturer: Eli Lilly. The KwikPen format is a convenient multi-dose pre-filled pen containing a monthly course of the medication. The device is designed so that patients can perform injections independently and virtually painlessly with high dosing precision.

Key Features:

✅ Advanced Level of Therapy: 12.5 mg is one of the final steps in dose titration, providing powerful glycemic control and a significant reduction in body mass index.
✅ Dual Effect: Acting on two hormonal pathways allows for more effective appetite suppression and optimized insulin production compared to previous generation drugs.
✅ Economy and Convenience: One KwikPen replaces four individual old-style pens, providing 4 full weekly injections.

Mounjaro 12.5 mg is prescribed for the following medical indications:

🔹 Type 2 Diabetes Mellitus: Long-term blood sugar control in adult patients when previous doses (5 mg, 7.5 mg, 10 mg) did not provide sufficient glycemic control.
🔹 Weight Management: Treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of cardiovascular complications, hypertension, or dyslipidemia.

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 12.5 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The drug is administered once a week. Transition to the 12.5 mg dose is only possible after successful completion of at least a 4-week course at the 10 mg dosage.
Injection Technique: Subcutaneous injection into the abdomen, front of the thigh, or upper arm. Rotate the injection site weekly.
Timing: Independent of meals. It is recommended to choose the same day of the week for ease of tracking.
Storage: Store in the refrigerator at 2°C–8°C. Do not freeze! After starting use, the pen can be stored at temperatures up to 30°C for 21 days.

⛔ Oncological Risks: Personal or family history of medullary thyroid carcinoma.
⛔ Endocrine Diseases: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
⛔ Pregnancy and Lactation: Use is contraindicated. When planning a pregnancy, use should be discontinued 2 months in advance.
⛔ Type 1 Diabetes Mellitus: Not intended for the treatment of this type of disease.
⛔ Severe GI Disorders: Severe gastroparesis or history of pancreatitis.
⛔ Allergy: Hypersensitivity to tirzepatide.

When using the 12.5 mg dosage, side effects related to the body's adaptation to a high concentration of the drug are possible:

🤢 Gastroenterological: Nausea, diarrhea, vomiting, dyspepsia, abdominal pain. Usually pronounced in the first weeks after a dose increase.
🍽️ Reduced Appetite: Rapid satiety and changes in taste preferences are frequently observed.
🏃‍♂️ General: Fatigue, feeling of weakness, sometimes dizziness (especially with low calorie intake).
⚠️ Serious Warnings: Monitoring of renal function is necessary in cases of severe vomiting (dehydration risk). Rarely — acute pancreatitis or gallbladder disease.
💉 Skin Reactions: Mild redness or itching at the injection site.